This review assessed the effects of disease management programmes, in managed care settings, for people with congestive heart failure, hypertension, and hyperlipidaemia and/or coronary heart disease. The author concluded that most programmes result in some improvement in measured outcomes. However, the conclusions should be treated with caution because of poorly reported review methodology and the uncertain quality of the included studies.
The author did not state how the papers were selected for the review, or how many reviewers performed the selection.
Assessment of study quality
The author did not state that they assessed validity.
Data extraction
The author did not state how the data were extracted for the review, or how many reviewers performed the data extraction. Details of the interventions and outcomes were abstracted in tables.
Methods of synthesis
How were the studies combined? A narrative discussion was presented, grouped according to disease and by study design.
How were differences between studies investigated? Study design was taken into consideration when discussing the outcomes. Other differences between the studies were also discussed.
Results of the review
Twenty studies (29,509 participants) were included: 6 RCTs, 3 controlled studies and 11 before-and-after studies. There were 4 RCTs on hypertension (1,734 participants) and two on hyperlipidaemia-CAD (4,469 participants); 2 controlled studies on hypertension (4,482 participants) and one on hyperlipidaemia-CAD (325 participants); and 5 before-andafter studies on CHF (2,078 participants) and three each on hypertension (638 participants) and hyperlipidaemia-CAD (15,783 participants).
CHF.
Five before-and-after studies assessed programmes for CHF. All showed benefits of the intervention: three showed improvements in hospital admission rates, length of stay or health care utilisation; two showed increased use of appropriate medication; and two showed improvements in functional status or clinical outcomes.
Hypertension.
Three RCTs reported benefits in the treatment groups in comparison with the control groups (variously: improvements in BP, lower hospital service utilisation, improved rates of follow-up visits and higher medication compliance).
Of the 2 controlled studies, one reported a benefit with treatment in increased appropriate drug use whilst the other reported no substantive gain in outcomes of BP control.
Of the 3 before-and-after design studies, one reported benefits in achieving BP goals but no differences in lifestyle modifications, although there was some improvement in quality-of-life outcomes; a second reported significant decreases in BP associated with improvements in lifestyle modifications; the third did not report the outcomes clearly.
Hyperlipidaemia-CAD.
One RCT reported little difference in changes in total cholesterol in the treatment and control groups. The second reported greater benefits in changes in cholesterol in the intervention group, although this study was limited to people hospitalised for acute myocardial infarction.
The controlled study showed no improvement in dietary knowledge after the intervention, but did not report on levels of cholesterol or clinical outcomes.
Three before-and-after studies showed improvements in risk factors, with an increase in the achievement of low-density
